NCT00121719View on ClinicalTrials.gov

An Open Label Dose Escalation Study Of E7080

PHASE1CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

July 1, 2005

Primary Completion Date

June 19, 2009

Study Completion Date

March 1, 2019

Conditions
Solid Tumor or Lymphoma
Interventions
DRUG

Lenvatinib

Lenvatinib tablets taken orally, once daily.

Trial Locations (2)

1066 Cx

Netherlands Cancer Institute- Antoni Van Leeuwenhoek Hospital, Amsterdam

G12 0Yn

Gartnavel General Hospital, Glasgow

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00121719 - An Open Label Dose Escalation Study Of E7080 | Biotech Hunter | Biotech Hunter